- Home
- PRME vs AMRN Comparison
PRME vs AMRN Comparison
Compare PRME & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- AMRN
- Stock Information
- Founded
- PRME 2019
- AMRN 1989
- Country
- PRME United States
- AMRN Ireland
- Employees
- PRME N/A
- AMRN N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- AMRN Health Care
- Exchange
- PRME Nasdaq
- AMRN Nasdaq
- Market Cap
- PRME 191.7M
- AMRN 216.0M
- IPO Year
- PRME 2022
- AMRN 1993
- Fundamental
- Price
- PRME $2.71
- AMRN $16.81
- Analyst Decision
- PRME Buy
- AMRN Strong Sell
- Analyst Count
- PRME 6
- AMRN 1
- Target Price
- PRME $9.38
- AMRN $12.00
- AVG Volume (30 Days)
- PRME 3.3M
- AMRN 183.4K
- Earning Date
- PRME 08-04-2025
- AMRN 07-30-2025
- Dividend Yield
- PRME N/A
- AMRN N/A
- EPS Growth
- PRME N/A
- AMRN N/A
- EPS
- PRME N/A
- AMRN N/A
- Revenue
- PRME $3,846,000.00
- AMRN $214,112,000.00
- Revenue This Year
- PRME $104.12
- AMRN N/A
- Revenue Next Year
- PRME $196.78
- AMRN $7.88
- P/E Ratio
- PRME N/A
- AMRN N/A
- Revenue Growth
- PRME 550.76
- AMRN N/A
- 52 Week Low
- PRME $1.11
- AMRN $7.08
- 52 Week High
- PRME $6.75
- AMRN $17.18
- Technical
- Relative Strength Index (RSI)
- PRME 69.76
- AMRN 76.05
- Support Level
- PRME $1.56
- AMRN $15.34
- Resistance Level
- PRME $2.78
- AMRN $17.18
- Average True Range (ATR)
- PRME 0.26
- AMRN 1.10
- MACD
- PRME 0.08
- AMRN 0.28
- Stochastic Oscillator
- PRME 76.81
- AMRN 92.42
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.